TI
CORT icon

Turner Investments’s Corcept Therapeutics CORT Stock Holding History

Turner Investments’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-14,000
Closed -$165K – 115
2017
Q2 		$165K Sell
14,000
-17,810
-56% -$194K 0.11% 207
2017
Q1 		$349K Buy
+31,810
New +$279K 0.23% 136

Other funds holding CORT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Turner Investments's CORT Position: Q3 2017 in Review

Turner Investments sold out of Corcept Therapeutics (CORT) in Q3 2017, closing a stake of 14,000 shares — an estimated $165K sold.

Turner Investments first reported a position in CORT in Q1 2017 and held it in 2 quarters. The position peaked at $349K in Q1 2017. 189 funds tracked by Wall St. Rank hold CORT as of Q3 2017.

  • Turner Investments reported no remaining Corcept Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Turner Investments sold 14,000 Corcept Therapeutics shares in Q3 2017, an estimated $165K.
  • Turner Investments first reported a position in Corcept Therapeutics in Q1 2017 and held it in 2 quarters.
  • Turner Investments's Corcept Therapeutics position peaked at $349K in Q1 2017.
  • 189 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2017.

Based on Turner Investments's 13F filing for Q3 2017, filed 8 Nov 2017.